These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30002742)

  • 21. Potential role of miR-100 in cancer diagnosis, prognosis, and therapy.
    Qin C; Huang RY; Wang ZX
    Tumour Biol; 2015 Mar; 36(3):1403-9. PubMed ID: 25740059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 23. Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies.
    Geeleher P; Zhang Z; Wang F; Gruener RF; Nath A; Morrison G; Bhutra S; Grossman RL; Huang RS
    Genome Res; 2017 Oct; 27(10):1743-1751. PubMed ID: 28847918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crosstalk in cancer resistance and metastasis.
    Norouzi S; Gorgi Valokala M; Mosaffa F; Zirak MR; Zamani P; Behravan J
    Crit Rev Oncol Hematol; 2018 Dec; 132():145-153. PubMed ID: 30447920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel biomarkers in cancer: The whole is greater than the sum of its parts.
    Samatov TR; Galatenko VV; Block A; Shkurnikov MY; Tonevitsky AG; Schumacher U
    Semin Cancer Biol; 2017 Aug; 45():50-57. PubMed ID: 27639751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
    Jankowska AM; Millward CL; Caldwell CW
    Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies.
    Calvo E; Walko C; Dees EC; Valenzuela B
    Am Soc Clin Oncol Educ Book; 2016; 35():e175-84. PubMed ID: 27249721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.
    Med Lett Drugs Ther; 2018 Jan; 60(1537):e8. PubMed ID: 29294466
    [No Abstract]   [Full Text] [Related]  

  • 29. Genomically guided cancer treatments: from "promising" to "clinically useful".
    Conley BA
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26023091
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumour biomarkers: homeostasis as a novel prognostic indicator.
    Falco M; Palma G; Rea D; De Biase D; Scala S; D'Aiuto M; Facchini G; Perdonà S; Barbieri A; Arra C
    Open Biol; 2016 Dec; 6(12):. PubMed ID: 27927793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 32. FcγRIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: A meta-analysis of genetic risk.
    Ziakas PD; Poulou LS; Zintzaras E
    J BUON; 2016; 21(6):1454-1458. PubMed ID: 28039707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
    Coté D; Eustace A; Toomey S; Cremona M; Milewska M; Furney S; Carr A; Fay J; Kay E; Kennedy S; Crown J; Hennessy B; Madden S
    PLoS One; 2018; 13(8):e0200996. PubMed ID: 30071039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Directly targeting transcriptional dysregulation in cancer.
    Gonda TJ; Ramsay RG
    Nat Rev Cancer; 2015 Nov; 15(11):686-94. PubMed ID: 26493648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Have Clinical Trials Properly Assessed c-Met Inhibitors?
    Hughes VS; Siemann DW
    Trends Cancer; 2018 Feb; 4(2):94-97. PubMed ID: 29458966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer Genetics and Implications for Clinical Management.
    Jamieson NB; Chang DK; Biankin AV
    Surg Clin North Am; 2015 Oct; 95(5):919-34. PubMed ID: 26315514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expansion platform type II: testing a treatment strategy.
    Catenacci DV
    Lancet Oncol; 2015 Oct; 16(13):1276-8. PubMed ID: 26342235
    [No Abstract]   [Full Text] [Related]  

  • 38. Predicting the outcome of chemotherapy for colorectal cancer.
    Allen WL; Coyle VM; Johnston PG
    Curr Opin Pharmacol; 2006 Aug; 6(4):332-6. PubMed ID: 16750422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of access to targeted cancer therapy.
    Burki TK
    Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.